Drugs / [18F]RCCB6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06680089 | Nov 2024 → Nov 2026 expected | kidney neoplasm | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]RCCB6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680089 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic efficacy of the above imaging agent” NCT06680089 ↗ |
| Target | CD70 | “CD70-targeted immunoPET/CT scanning.” NCT06680089 ↗ |